厄贝沙坦与依那普利治疗轻中度原发性高血压疗效与安全性比较的Meta分析

目的:比较厄贝沙坦与依那普利治疗轻、中度原发性高血压的疗效及安全性。方法:应用Meta分析对有关厄贝沙坦与依那普利治疗轻、中度原发性高血压的有效性、安全性进行定量综合分析,共入选21项研究可进行同质性检验及合并效应量的估计。结果:(1)同质性检验:有效性,χ2=26.00,自由度(df)=20;安全性,χ2=17.02,df=19,二者P值均>0.05。(2)合并效应量估计:有效性的OR合并=1.94(95%可信区间为1.53～2.44)。合并效应量的检验Z=5.58,P<0.00001;安全性的OR合并=0.32(95%可信区间为0.24～0.43)。合并效应量的检验Z=7.62,P<0.00001。结论:厄贝沙坦治疗轻、中度原发性高血压的总体疗效明显优于依那普利,而不良反应的发生总体上低于依那普利。

Meta-analysis of Clinical Efficacy and Safety of Irbesartan vs. Enalapril in the Treatment of Mild and Moderate Primary Hypertension

OBJECTIVE：To compare the clinical efficacy and safety of irbesartan vs. enalapril in the treatment of mild and moderate parimary hypertension. METHODS：The clinical efficacy and safety of irbesartan vs. enalapril in the treatment of mild and moderate primary hypertension were qualitatively analyzed by meta-analysis. The homogeneity test and combined test were carried out in 21 included literatures. RESULTS：Homogeneity test showed clinical efficacy and safety with χ2=26.00 （df =20） and χ2=17.02 （df =19） （P〉0.05）; and in combined test,the combined ORe=1.94 （95% confidence interval ranged from 1.53 to 2.44,Z=5.58,P〈0.000 01） and combined ORs=0.32（95% confidence interval 0.24～0.43,Z=7.62,P〈0.000 01）. CONCLUSION：Clinical efficacy and safety of irbesartan is significantly better than enalapril in treatment of mild and moderate primary hypertension. But the incidence of ADR induced by irbesartan is lower than enalapril-induced ADR.